-
1
-
-
78449281377
-
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
-
Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
-
(2010)
Lancet
, vol.376
, pp. 1670-1681
-
-
Baigent, C.1
Blackwell, L.2
Emberson, J.3
Holland, L.E.4
Reith, C.5
Bhala, N.6
-
2
-
-
84862119222
-
European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
-
* Developed with the special contribution of the European Association for Cardiovascular
-
Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2012, 33:1635-1701.
-
(2012)
Eur. Heart J.
, vol.33
, pp. 1635-1701
-
-
Perk, J.1
De Backer, G.2
Gohlke, H.3
Graham, I.4
Reiner, Z.5
Verschuren, M.6
-
3
-
-
84893935789
-
An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia - full report
-
Grundy S.M., Arai H., Barter P., Berso T.P., Betteridge D.J., Carmena R., et al. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia - full report. J.Clin. Lipidol. 2014, 8:29-60.
-
(2014)
J.Clin. Lipidol.
, vol.8
, pp. 29-60
-
-
Grundy, S.M.1
Arai, H.2
Barter, P.3
Berso, T.P.4
Betteridge, D.J.5
Carmena, R.6
-
4
-
-
84872712625
-
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
-
Anderson T.J., Grégoire J., Hegele R.A., Couture P., Mancini G.B., McPherson R., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 2013, 29:151-167.
-
(2013)
Can. J. Cardiol.
, vol.29
, pp. 151-167
-
-
Anderson, T.J.1
Grégoire, J.2
Hegele, R.A.3
Couture, P.4
Mancini, G.B.5
McPherson, R.6
-
5
-
-
67651111687
-
Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals
-
Waters D.D., Brotons C., Chiang C.W., Ferrieres J., Foody J., Jukema J.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
-
(2009)
Circulation
, vol.120
, pp. 28-34
-
-
Waters, D.D.1
Brotons, C.2
Chiang, C.W.3
Ferrieres, J.4
Foody, J.5
Jukema, J.W.6
-
6
-
-
61849116330
-
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries
-
Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
-
(2009)
Lancet
, vol.373
, pp. 929-940
-
-
Kotseva, K.1
Wood, D.2
De Backer, G.3
De Bacquer, D.4
Pyorala, K.5
Keil, U.6
-
7
-
-
84897970506
-
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
-
Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 129(25 Suppl.2):S1-S45.
-
(2013)
Circulation
, vol.129
, Issue.25 SUPPL.2
, pp. S1-S45
-
-
Stone, N.J.1
Robinson, J.G.2
Lichtenstein, A.H.3
Bairey Merz, C.N.4
Blum, C.B.5
Eckel, R.H.6
-
8
-
-
0030972796
-
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
-
Roberts W. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol. 1997, 80:106-107.
-
(1997)
Am. J. Cardiol.
, vol.80
, pp. 106-107
-
-
Roberts, W.1
-
9
-
-
72049130254
-
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)
-
Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol. 2010, 105:69-76.
-
(2010)
Am. J. Cardiol.
, vol.105
, pp. 69-76
-
-
Nicholls, S.J.1
Brandrup-Wognsen, G.2
Palmer, M.3
Barter, P.J.4
-
11
-
-
35748962429
-
The safety of statins in clinical practice
-
Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
-
(2007)
Lancet
, vol.370
, pp. 1781-1790
-
-
Armitage, J.1
-
12
-
-
84864915536
-
Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients
-
Karalis D.G., Victor B., Ahedor L., Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol 2012, 861924.
-
(2012)
Cholesterol
, pp. 861924
-
-
Karalis, D.G.1
Victor, B.2
Ahedor, L.3
Liu, L.4
-
13
-
-
77649195191
-
Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
-
Willey V.J., Bullano M.F., Shoetan N.N., Gandhi S.K. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr. Med. Res. Opin. 2010, 26:121-128.
-
(2010)
Curr. Med. Res. Opin.
, vol.26
, pp. 121-128
-
-
Willey, V.J.1
Bullano, M.F.2
Shoetan, N.N.3
Gandhi, S.K.4
-
14
-
-
77950346846
-
LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice
-
Rublee D.A., Burke J.P. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad. Med. 2010, 122:16-24.
-
(2010)
Postgrad. Med.
, vol.122
, pp. 16-24
-
-
Rublee, D.A.1
Burke, J.P.2
-
15
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N.Engl. J. Med. 2011, 365:2255-2267.
-
(2011)
N.Engl. J. Med.
, vol.365
, pp. 2255-2267
-
-
-
16
-
-
84877299845
-
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
-
HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291.
-
(2013)
Eur. Heart J.
, vol.34
, pp. 1279-1291
-
-
-
17
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N.Engl. J. Med. 2010, 362:1563-1574.
-
(2010)
N.Engl. J. Med.
, vol.362
, pp. 1563-1574
-
-
-
18
-
-
84905040766
-
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population
-
Blazing M.A., Giugliano R.P., Cannon C.P., Musliner T.A., Tershakovec A.M., White J.A., et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am. Heart J. 2014, 168:205-212.
-
(2014)
Am. Heart J.
, vol.168
, pp. 205-212
-
-
Blazing, M.A.1
Giugliano, R.P.2
Cannon, C.P.3
Musliner, T.A.4
Tershakovec, A.M.5
White, J.A.6
-
19
-
-
78149457142
-
Update on the efficacy and safety of combination ezetimibe plus statin therapy
-
Toth P.P., Catapano A., Tomassini J.E., Tershakovec A.M. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin. Lipidol. 2010, 5:655-684.
-
(2010)
Clin. Lipidol.
, vol.5
, pp. 655-684
-
-
Toth, P.P.1
Catapano, A.2
Tomassini, J.E.3
Tershakovec, A.M.4
-
20
-
-
84889813405
-
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
-
Foody J.M., Toth P.P., Tomassini J.E., Sajjan S., Ramey D.R., Neff D., et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc. Health Risk Manag. 2013, 9:719-727.
-
(2013)
Vasc. Health Risk Manag.
, vol.9
, pp. 719-727
-
-
Foody, J.M.1
Toth, P.P.2
Tomassini, J.E.3
Sajjan, S.4
Ramey, D.R.5
Neff, D.6
-
21
-
-
84856358934
-
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study
-
Hing Ling P.K., Civeira F., Dan A.G., Hanson M.E., Massaad R., De Tilleghem Cle B., et al. Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis. 2012, 11:18.
-
(2012)
Lipids Health Dis.
, vol.11
, pp. 18
-
-
Hing Ling, P.K.1
Civeira, F.2
Dan, A.G.3
Hanson, M.E.4
Massaad, R.5
De Tilleghem Cle, B.6
-
22
-
-
62549118503
-
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study
-
Farnier M., Averna M., Missault L., Vaverkova H., Viigimaa M., Massaad R., et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study. Int. J. Clin. Pract. 2009, 63:547-559.
-
(2009)
Int. J. Clin. Pract.
, vol.63
, pp. 547-559
-
-
Farnier, M.1
Averna, M.2
Missault, L.3
Vaverkova, H.4
Viigimaa, M.5
Massaad, R.6
-
23
-
-
79960901604
-
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)
-
Bays H.E., Davidson M.H., Massaad R., Flaim D., Lowe R.S., Tershakovec A.M., et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am. J. Cardiol. 2011, 108:523-530.
-
(2011)
Am. J. Cardiol.
, vol.108
, pp. 523-530
-
-
Bays, H.E.1
Davidson, M.H.2
Massaad, R.3
Flaim, D.4
Lowe, R.S.5
Tershakovec, A.M.6
-
24
-
-
76849095375
-
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or= 65 years of age (from the ZETia in the ELDerly [ZETELD] study)
-
Zieve F., Wenger N.K., Ben Yehuda O., Constance C., Bird S., Lee R., et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or= 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am. J. Cardiol. 2010, 106:656-663.
-
(2010)
Am. J. Cardiol.
, vol.106
, pp. 656-663
-
-
Zieve, F.1
Wenger, N.K.2
Ben Yehuda, O.3
Constance, C.4
Bird, S.5
Lee, R.6
-
25
-
-
84888585549
-
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia
-
Bays H.E., Averna M., Majul C., Muller-Wieland D., De Pellegrin A., Giezek H., et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am. J. Cardiol. 2013, 112:1885-1895.
-
(2013)
Am. J. Cardiol.
, vol.112
, pp. 1885-1895
-
-
Bays, H.E.1
Averna, M.2
Majul, C.3
Muller-Wieland, D.4
De Pellegrin, A.5
Giezek, H.6
-
26
-
-
84864753387
-
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials
-
Morrone D., Weintraub W.S., Toth P.P., Hanson M.E., Lowe R.S., Lin J., et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261. 10.1016/j.atherosclerosis.2012.02.016.
-
(2012)
Atherosclerosis
, vol.223
, pp. 251-261
-
-
Morrone, D.1
Weintraub, W.S.2
Toth, P.P.3
Hanson, M.E.4
Lowe, R.S.5
Lin, J.6
-
27
-
-
0037111890
-
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
-
Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 2002, 90:1084-1091.
-
(2002)
Am. J. Cardiol.
, vol.90
, pp. 1084-1091
-
-
Gagne, C.1
Bays, H.E.2
Weiss, S.R.3
Mata, P.4
Quinto, K.5
Melino, M.6
-
28
-
-
18244390229
-
Acommunity-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial
-
Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., Palmisano J. Acommunity-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 2005, 80:587-595.
-
(2005)
Mayo Clin. Proc.
, vol.80
, pp. 587-595
-
-
Pearson, T.A.1
Denke, M.A.2
McBride, P.E.3
Battisti, W.P.4
Brady, W.E.5
Palmisano, J.6
-
29
-
-
18744376636
-
LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia
-
Brohet C., Banai S., Alings A.M., Massaad R., Davies M.J., Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr. Med. Res. Opin. 2005, 21:571-578.
-
(2005)
Curr. Med. Res. Opin.
, vol.21
, pp. 571-578
-
-
Brohet, C.1
Banai, S.2
Alings, A.M.3
Massaad, R.4
Davies, M.J.5
Allen, C.6
-
30
-
-
20744455079
-
Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease
-
Farnier M., Volpe M., Massaad R., Davies M.J., Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int. J. Cardiol. 2005, 102:327-332.
-
(2005)
Int. J. Cardiol.
, vol.102
, pp. 327-332
-
-
Farnier, M.1
Volpe, M.2
Massaad, R.3
Davies, M.J.4
Allen, C.5
-
31
-
-
23844497814
-
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease
-
Cruz-Fernandez J.M., Bedarida G.V., Adgey J., Allen C., Johnson-Levonas A.O., Massaad R. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int. J. Clin. Pract. 2005, 59:619-627.
-
(2005)
Int. J. Clin. Pract.
, vol.59
, pp. 619-627
-
-
Cruz-Fernandez, J.M.1
Bedarida, G.V.2
Adgey, J.3
Allen, C.4
Johnson-Levonas, A.O.5
Massaad, R.6
-
32
-
-
3142696484
-
Coadministration of ezetimibe with simvastatin
-
Dobs A.S., Guyton J.R., McClusky D., Ponsonnet D., Melani L., Lebeaut A., et al. Coadministration of ezetimibe with simvastatin. J.Am. Coll. Cardiol. 2003, 41:227A.
-
(2003)
J.Am. Coll. Cardiol.
, vol.41
, pp. 227A
-
-
Dobs, A.S.1
Guyton, J.R.2
McClusky, D.3
Ponsonnet, D.4
Melani, L.5
Lebeaut, A.6
-
33
-
-
4644256971
-
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin
-
Stein E., Stender S., Mata P., Sager P., Ponsonnet D., Melani L., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. 2004, 148:447-455.
-
(2004)
Am. Heart J.
, vol.148
, pp. 447-455
-
-
Stein, E.1
Stender, S.2
Mata, P.3
Sager, P.4
Ponsonnet, D.5
Melani, L.6
-
34
-
-
12744274866
-
Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients
-
Gaudiani L.M., Lewin A., Meneghini L., Perevozskaya I., Plotkin D., Mitchel Y., et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes. Metab. 2005, 7:88-97.
-
(2005)
Diabetes Obes. Metab.
, vol.7
, pp. 88-97
-
-
Gaudiani, L.M.1
Lewin, A.2
Meneghini, L.3
Perevozskaya, I.4
Plotkin, D.5
Mitchel, Y.6
-
35
-
-
58149473593
-
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus up-titration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease
-
Conard S.E., Bays H.E., Leiter L.A., Bird S.R., Rubino J., Lowe R.S., et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus up-titration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am. J. Cardiol. 2008, 102:1489-1494.
-
(2008)
Am. J. Cardiol.
, vol.102
, pp. 1489-1494
-
-
Conard, S.E.1
Bays, H.E.2
Leiter, L.A.3
Bird, S.R.4
Rubino, J.5
Lowe, R.S.6
-
36
-
-
58149472552
-
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with up-titration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease
-
Leiter L.A., Bays H., Conard S., Bird S., Rubino J., Hanson M.E., et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with up-titration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am. J. Cardiol. 2008, 102:1495-1501.
-
(2008)
Am. J. Cardiol.
, vol.102
, pp. 1495-1501
-
-
Leiter, L.A.1
Bays, H.2
Conard, S.3
Bird, S.4
Rubino, J.5
Hanson, M.E.6
-
37
-
-
33645235185
-
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease
-
Barrios V., Amabile N., Paganelli F., Chen J.W., Allen C., Johnson-Levonas A.O., et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int. J. Clin. Pract. 2005, 59:1377-1386.
-
(2005)
Int. J. Clin. Pract.
, vol.59
, pp. 1377-1386
-
-
Barrios, V.1
Amabile, N.2
Paganelli, F.3
Chen, J.W.4
Allen, C.5
Johnson-Levonas, A.O.6
-
38
-
-
34347399601
-
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus
-
Constance C., Westphal S., Chung N., Lund M., McCrary Sisk C., Johnson-Levonas A.O., et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2007, 9:575-584.
-
(2007)
Diabetes Obes. Metab.
, vol.9
, pp. 575-584
-
-
Constance, C.1
Westphal, S.2
Chung, N.3
Lund, M.4
McCrary Sisk, C.5
Johnson-Levonas, A.O.6
-
39
-
-
84873435386
-
Acomparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease
-
Rosen J.B., Jimenez J.B., Pirags V., Vides H., Hanson M.E., Massaad R., et al. Acomparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes Vasc. Dis. Res. 2013, 10:277-286.
-
(2013)
Diabetes Vasc. Dis. Res.
, vol.10
, pp. 277-286
-
-
Rosen, J.B.1
Jimenez, J.B.2
Pirags, V.3
Vides, H.4
Hanson, M.E.5
Massaad, R.6
-
40
-
-
51549108029
-
Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation
-
Ara R., Tumur I., Pandor A., Duenas A., Williams R., Wilkinson A., et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol. Assess. 2008, 12:21.
-
(2008)
Health Technol. Assess.
, vol.12
, pp. 21
-
-
Ara, R.1
Tumur, I.2
Pandor, A.3
Duenas, A.4
Williams, R.5
Wilkinson, A.6
-
41
-
-
84893937252
-
Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease
-
Toth P.P., Foody J.M., Tomassini J.E., Sajjan S.G., Ramey D.R., Neff D.R., et al. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J.Clin. Lipidol. 2014, 8:107-116.
-
(2014)
J.Clin. Lipidol.
, vol.8
, pp. 107-116
-
-
Toth, P.P.1
Foody, J.M.2
Tomassini, J.E.3
Sajjan, S.G.4
Ramey, D.R.5
Neff, D.R.6
-
42
-
-
84884341099
-
Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
-
Torimoto K., Okada Y., Mori H., Hajime M., Tanaka K., Kurozumi A., et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013, 12:137.
-
(2013)
Lipids Health Dis.
, vol.12
, pp. 137
-
-
Torimoto, K.1
Okada, Y.2
Mori, H.3
Hajime, M.4
Tanaka, K.5
Kurozumi, A.6
-
43
-
-
41149096040
-
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study
-
Roeters van Lennep H.W., Liem A.H., Dunselman P.H., Dallinga-Thie G.M., Zwinderman A.H., Jukema J.W. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr. Med. Res. Opin. 2008, 24:685-694.
-
(2008)
Curr. Med. Res. Opin.
, vol.24
, pp. 685-694
-
-
Roeters van Lennep, H.W.1
Liem, A.H.2
Dunselman, P.H.3
Dallinga-Thie, G.M.4
Zwinderman, A.H.5
Jukema, J.W.6
-
44
-
-
37849034077
-
Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting
-
Harley C.R., Gandhi S.K., Anoka N., Bullano M.F., McKenney J.M. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting. Am. J. Manag. Care 2007, 13:S276-S281.
-
(2007)
Am. J. Manag. Care
, vol.13
, pp. S276-S281
-
-
Harley, C.R.1
Gandhi, S.K.2
Anoka, N.3
Bullano, M.F.4
McKenney, J.M.5
-
45
-
-
0037126729
-
Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
-
National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
|